Mail

NOVN - Novan, Inc.

NasdaqGM - NasdaqGM Real Time Price. Currency in USD

1.9000

+0.2200 (+13.10%)

At close: 4:00PM EDT

Stock chart is not supported by your current browser

Previous Close	1.6800
Open	1.7900
Bid	0.0000 x 1100
Ask	0.0000 x 800
Day's Range	1.7000 - 2.0900
52 Week Range	0.6500 - 3.2500
Volume	783,447
Avg. Volume	401,487

Market Cap	49.514M
Beta (3Y Monthly)	N/A
PE Ratio (TTM)	N/A
EPS (TTM)	-0.5560
Earnings Date	N/A
Forward Dividend & Yield	N/A (N/A)
Ex-Dividend Date	N/A
1y Target Est	6.00

Trade prices are not sourced from all markets

All

News

Press Releases

Zacks5 days ago
Is WisdomTree International High Dividend Fund (DTH) a Strong ETF Right Now?
Smart Beta ETF report for DTH
American City Business Journals5 days ago
With a fresh $30 million, Durham pharma set to expand drug pipeline
With a $30 million investment from a single Cary-based firm, one Durham pharmaceutical company is "set loose" to run multiple trials.
GlobeNewswire13 days ago
Novan to Present Clinical Data at Annual Meeting of the Society for Investigative Dermatology
Novan, Inc. ("the Company" or "Novan") (NOVN) today announced that recent data from the Company’s Phase 1b trial with SB414 cream for the treatment of atopic dermatitis and Phase 2 trial with SB206 gel for the treatment of molluscum contagiosum will be presented at the 77th Annual Meeting of the Annual Meeting of the Society for Investigative Dermatology. Clinical and biomarker results from the Company’s Phase 1b atopic dermatitis trial will be presented during an oral presentation on May 9, 2019 and during a poster session on May 11, 2019.
American City Business Journals14 days ago
Novan adds more cash, now confident it can execute
In an continued effort to fund the company without hurting its already-down stock value, Novan has announced another $12 million deal to forward its lead drug trials.
GlobeNewswire15 days ago
Novan Completes Funding Transaction with Ligand Pharmaceuticals
Novan, Inc. ("the Company" or "Novan") (NOVN) today announced that the Company has secured $12 million in non-dilutive capital from Ligand Pharmaceuticals Incorporated (“Ligand”) (LGND). This transaction further enables the accelerated advancement of the molluscum Phase 3 program within the overall Novan mid-to-late stage clinical development portfolio. Under the terms of this development funding and royalty agreement, Ligand will provide funding of $12 million in exchange for a tiered royalty of 7 to 10% which will be based on future North American sales of SB206 for the molluscum indication.
GlobeNewswire20 days ago
Novan Confirms Corporate Update Conference Call and Webcast
Novan, Inc. ("the Company" or "Novan") (NOVN) today confirmed that the Company will host a conference call tomorrow, Thursday, May 2, 2019 at 8:15 am Eastern Time to provide an update on the Company’s recent financing, clinical development plan and business model.
American City Business Journals21 days ago
Cash-starved Novan adds capital, but at a price
With just a over a month of its cash runway left, Novan has come up big with $35 million – but that capital comes with strings attached.
GlobeNewswire21 days ago
Novan Secures Up to $35 Million in Non-Dilutive Funding
Novan, Inc. ("the Company" or "Novan") (NOVN) today announced that the Company has secured up to $35 million in non-dilutive capital to advance Novan’s late-stage dermatology assets. Of this, $25 million is available immediately and $10 million is contingent upon achieving positive Phase 3 clinical trial results for molluscum contagiosum. This funding will allow Novan to immediately initiate the pivotal Phase 3 molluscum program.
American City Business Journals2 months ago
Novan stock plummets as Durham company searches for additional financing
One of the Triangle’s public companies continues to face hardships, as Novan’s stock dives away from the value it needs to stay on the stock exchange.
Zacks2 months ago
Will NOVAN INC (NOVN) Report Negative Q4 Earnings? What You Should Know
NOVAN INC (NOVN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
GlobeNewswire2 months ago
Novan and Sato Advance Japan Market and Dermatology Partnership
Novan, Inc. ("the Company" or "Novan") (NOVN) today announced that the Company has named Dr. Elizabeth Messersmith, the Company’s Senior Vice President and Chief Development Officer, the chairperson of the Joint Committee responsible for overseeing the Company’s alliance with Sato Pharmaceutical Co., Ltd. (“Sato”).
GlobeNewswire2 months ago
Novan Completes End-of-Phase 2 Meeting and Provides Additional Business Updates
Novan, Inc. ("the Company" or "Novan") (NOVN) today announced a number of recent business advancements. Novan concluded an end-of-Phase 2 meeting with the U.S. Food and Drug Administration (FDA) regarding SB206 for the treatment of molluscum.
GlobeNewswire3 months ago
Novartis Cosentyx® shows superior improvements in psoriasis patients' quality of life versus Janssen's IL-23 Stelara®*
New CLARITY data show over two-thirds of Cosentyx (secukinumab) treated patients with moderate to severe psoriasis reported no impact of skin disease on their quality of life (QoL) up to Week 16 compared ...
GlobeNewswire3 months ago
Novartis data confirm rapid response and high efficacy of Cosentyx® in psoriasis patients for first time in China
Phase III study shows close to 9/10 patients who received Cosentyx® 300mg achieved clear or almost clear skin during the first 16 weeks of treatment (87%), with rapid onset of relief seen as early as week ...
GlobeNewswire3 months ago
Novartis shareholders approve all resolutions proposed by the Board of Directors at the Annual General Meeting
Shareholders approve 22 nd consecutive dividend increase to CHF 2.85 (+2%) per share for 2018; representing a 3.1% yield and approximately 57% payout of free cash flow Overwhelming majority of shareholders ...
GlobeNewswire3 months ago
Novartis issues summary financial information for the Alcon eye care business ahead of shareholder vote on proposed spin-off
Basel, February 25, 2019 - Novartis today published certain key financial information for the Alcon eye care business covering the full year 2018 ahead of a vote on the proposed 100% spin-off of Alcon ...
GlobeNewswire3 months ago
Novartis to pursue transformational therapy to reduce risk of cardiovascular disease in people living with elevated levels of inherited lipoprotein(a)
Novartis announced today that it is exercising its option to license the rights to develop and commercialize TQJ230, an investigational agent previously known as AKCEA-APO(a)-LRx, from Akcea Therapeutics, ...
GlobeNewswire3 months ago
Novartis receives FDA approval for Egaten® for the treatment of fascioliasis, a neglected tropical disease
Novartis announced today that the US Food and Drug Administration (FDA) has approved Egaten® (triclabendazole) for the treatment of fascioliasis in patients six years of age and older. This makes Egaten the only FDA-approved drug for people with this disease and is expected to facilitate broader access to this important drug not only in the US, but also in affected countries worldwide.
GlobeNewswire4 months ago
Novan Provides Business Update
Novan, Inc. ("the Company" or "Novan") (NOVN) today provided an update on several aspects of its business. Novan announces that it has been granted an end-of-Phase 2 meeting with the FDA in early March 2019 for the SB206 molluscum program.
American City Business Journals4 months ago
Novan faces delisting from Nasdaq
After years and ups and downs while the company has been trying to push out their nitric oxide candidates, Novan now faces a delisting threat due to steadily decreasing stock value.
American City Business Journals5 months ago
Novan shakes up leadership again
Leadership at Novan is shifting again, with several executives changing roles as the company shifts its strategic focuses.
CNBC Videos4 months ago
Cramer's Exec Cut: The biggest names in health—and Apple—...
Jim Cramer gets a fresh perspective on health-care innovation with Apple, Dexcom, Canopy Growth and more.
CNBC Videos4 months ago
Novartis CEO on chasing cures over profitable treatments
Jim Cramer and Novartis CEO Vas Narasimhan discuss how the drugmaker is refocusing its business to leverage new-age treatments and potential cures.